AIM - AIM ImmunoTech's Ampligen extends survival in pancreatic cancer patients

AIM ImmunoTech (AIM) jumps 35% premarket on robust volume in reaction to its announcement of results from an Ampligen multiyear early access program in the Netherlands for pancreatic cancer patients.A medical team at Erasmus University Medical Center ((EUMC)) reported a significant survival benefit from Ampligen in patients with locally advanced or metastatic pancreatic cancer following chemotherapy. Specifically, survival in the group receiving the pluripotent toll-like receptor 3 (TLR3) agonist was 200% greater than than historical controls.The company says it will work with CRO Amarex Clinical Research, LLC to seek accelerated review status in the U.S. and FDA sign-off on a follow-up Phase 2/3 clinical trial in pancreatic cancer with sites in the Netherlands including EUMC.

For further details see:

AIM ImmunoTech's Ampligen extends survival in pancreatic cancer patients